Servier's $2.5 Billion Acquisition of Day One: Strategic Implications
Servier's acquisition of Day One Biopharmaceuticals for $2.5 billion could reshape its position in the pediatric oncology market, but risks remain.
Editorial Staff Mar 6
Medicine
Latest Medicine stories from Life.
Strategic view: FDA-UniQure Tussle and Pfizer's Obesity Drug Approval in China
Strategic implications in focus: China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more crowded.
Editorial Staff Mar 6